Patents by Inventor Alain Munafo

Alain Munafo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cladribine regimen for treating multiple sclerosis
    Patent number: 8377903
    Abstract: The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: February 19, 2013
    Assignee: Merck Serono SA
    Inventors: Giampiero De Luca, Arnaud Ythier, Alain Munafo, Maria Lopez-Bresnahan
  • Cladribine Regimen for Treating Multiple Sclerosis
    Publication number: 20100203017
    Abstract: The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible.
    Type: Application
    Filed: April 23, 2010
    Publication date: August 12, 2010
    Applicant: Merck Serono S.A.
    Inventors: Giampiero De Luca, Arnaud Ythier, Alain Munafo, Maria Lopez-Bresnahan
  • Cladribine regimen for treating multiple sclerosis
    Patent number: 7713947
    Abstract: The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be orally administered and wherein re-treatments are possible.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: May 11, 2010
    Assignee: Merck Serono S.A.
    Inventors: Giampiero De Luca, Arnaud Ythier, Alain Munafo, Maria Lopez-Bresnahan
  • DOSING METHODS FOR TREATING AUTOIMMUNE DISEASES USING A TACI-Ig FUSION PROTEIN SUCH AS ATACICEPT
    Publication number: 20090186040
    Abstract: In various embodiments, the present invention provides methods, compositions, dosing, and administration schedules for treatment of autoimmune diseases, including systemic erythematosus (SLE), for example, comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule such as atacicept. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BLyS and APRIL, in particular the use of multiple administrations of the fusion molecule at relatively low dose over the course of the treatment.
    Type: Application
    Filed: June 13, 2008
    Publication date: July 23, 2009
    Inventors: Sharon J. Busby, Jane A. Gross, Jennifer Visich, Ivan Nestorov, Alain Munafo, Orestis Papasouliotis, Claudia Pena Rossi